Trial of tipranavir versus darunavir in treatment-experienced patients enrolling.
D000293:Adolescent; D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D017327:Clinical Trials, Phase IV as Topic / Q000379:methods*; D000069454:Darunavir; D024882:Drug Resistance, Viral; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008297:Male; D018579:Patient Selection; D011725:Pyridines / Q000008:administration & dosage / Q000627:therapeutic use; D011753:Pyrones / Q000008:administration & dosage / Q000627:therapeutic use; D012107:Research Design; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use; D019562:Viral Load
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D011725:Pyridines; D011753:Pyrones; D013449:Sulfonamides; D000069454:Darunavir; C107201:tipranavir